POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).

被引：6
|
作者：
Golan, Talia
Oh, Do-Youn
Reni, Michele
Macarulla, Teresa Mercade
Tortora, Giampaolo
Hall, Michael J.
Reinacher-Schick, Anke C.
Borg, Christophe
Hochhauser, Daniel
Walter, Thomas
Hochster, Howard S.
Baker, Nigel
Locker, Gershon Y.
Kindler, Hedy L.
机构：
[1] Sheba Med Ctr, Oncol Inst, Tel Hashomer, Israel
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Hosp San Raffaele, Milan, Italy
[4] Vall Hebron Univ Hosp HUVH, Barcelona, Spain
[5] Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[6] Med Sch, Verona, Italy
[7] Univ Hosp, Verona, Italy
[8] Fox Chase Canc Ctr, Philadelphia, PA USA
[9] Klinikum Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[10] Hop Jean Minjoz, Besancon, France
[11] UCL, UCL Canc Inst, London, England
[12] Hop Edouard Herriot, Lyon, France
[13] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA
[14] AstraZeneca, Cambridge, England
[15] AstraZeneca, Gaithersburg, MD USA
[16] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4152
引用
收藏
页数：2
相关论文
共 50 条
  • [1] POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy.
    Kindler, Hedy Lee
    Locker, Gershon Y.
    Mann, Helen
    Golan, Talia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
    Reni, Michele
    Kindler, Hedy L.
    Hammel, Pascal
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui, Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Golani, Talia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [3] Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
    Algul, H.
    Reni, M.
    Kindler, H. L.
    Hammel, P.
    Van Cutsem, E.
    Macarulla, T.
    Hall, M. J.
    Park, J. O.
    Hochhauser, D.
    Arnold, D.
    Oh, D-Y
    Reinacher-Schick, A.
    Tortora, G.
    O'Reilly, E.
    McGuiness, D.
    Cui, K.
    Schlienger, K.
    Locker, G.
    Golan, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 216 - 216
  • [4] Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial
    Hochhauser, D.
    Kindler, H.
    Hammel, P.
    Reni, M.
    Van Cutsem, E.
    Macarulla, T.
    Hall, M. J.
    Park, J. O.
    Arnold, D.
    Oh, D-Y.
    Reinacher-Schick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E. M.
    McGuinness, D.
    Cui, K.
    Schlienger, K.
    Locker, G.
    Golan, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S940 - S941
  • [5] Early progression in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) vs placebo (P)
    Reinacher-Schick, A.
    Macarulla, T.
    Kindler, H. L.
    Hammel, P.
    Reni, M.
    Van Cutsem, E.
    Hall, M. J.
    Park, J-O
    Hochhauser, D.
    Arnold, D.
    Oh, D-Y
    Tortora, G.
    Alguel, H.
    O'Reilly, E. M.
    McGuinness, D.
    Cui, K.
    Schlienger, K.
    Locker, G. Y.
    Golan, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 218 - 219
  • [6] Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial
    Kindler, H.
    Hammel, P.
    Reni, M.
    Van Cutsem, E.
    Macarulla, T.
    Hall, M.
    Park, J.
    Hochhauser, D.
    Arnold, D.
    Oh, D.
    Reinacher-Schick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E.
    McGuinness, D.
    Cui, K.
    Schlienger, K.
    Locker, G.
    Golan, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S218 - S218
  • [7] Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P)
    Macarulla, Teresa
    Kindler, Hedy L.
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui, Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Golan, Talia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
    Zhan, Mei
    Zheng, Hanrui
    Yang, Yu
    He, Zhiyao
    Xu, Ting
    Li, Qiu
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12919 - 12926
  • [9] POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
    Van Cutsem, E.
    Golan, T.
    Hammel, P.
    Reni, M.
    Macarulla, T.
    Hall, M. J.
    Park, J. O.
    Hochhauser, D.
    Arnold, D.
    Oh, D-Y.
    Reinacher-Schick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E. M.
    McGuinness, D.
    Cui, K. Y.
    Schlienger, K.
    Locker, G. Y.
    Kindler, H. L.
    ANNALS OF ONCOLOGY, 2019, 30 : 264 - +
  • [10] Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
    Hall, Michael J.
    Golan, Talia
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui, Karen
    Joo, Seongjung
    Yoo, Hyun Kyoo
    Patel, Nikunj
    Kindler, Hedy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345